Heterogeneous expression of protein and mRNA in pyruvate dehydrogenase deficiency.

Publisher Website
Google Scholar
Abstract
Deficiency of pyruvate dehydrogenase [pyruvate:lipoamide 2-oxidoreductase (decarboxylating and acceptor-acetylating), EC 1.2.4.1], the first component of the pyruvate dehydrogenase complex, is associated with lactic acidosis and central nervous system dysfunction. Using both specific antibodies to pyruvate dehydrogenase and cDNAs coding for its two .alpha. and .beta. subunits, we characterized pyruvate dehydrogenase deficiency in 11 patients. Three different patterns were found on immunologic and RNA blot analyses. (i) Seven patients had immunologically detectable crossreactive material for the .alpha. and .beta. proteins of pyruvate dehydrogenase. (ii) Two patients had no detectable crossreactive protein for either the .alpha. or .beta. subunit but had normal amounts of mRNA for both .alpha. and .beta. subunits. (iii) The remaining two patients also had no detectable crossreactive protein but had diminished amounts of mRNA for the .alpha. subunit of pyruvate dehydrogenase only. These results indicate that loss of pyruvate dehydrogenase activity may be associated with either absent or catalytically inactive proteins, and in those cases in which this enzyme is absent, mRNA for one of the subunits may also be missing. When mRNA for one of the subunits is lacking, both protein subunits are absent, suggesting that a mutation affecting the expression of one of the subunit proteins causes the remaining uncomplexed subunit to be unstable. The results show that several different mutations account for the molecular heterogeneity of pyruvate dehydrogenase deficiency.